| Objective To explore the effect of levosimendan on cardiac function in patients with chronic heart failure with dilated cardiomyopathy and its therapeutic effect. Methods Sixty patients with dilated cardiomyopathy and heart failure received treatment at Ningde City Hospital of Fujian Province from June 2015 to Dec 2016 were selected. Patients were numbered with hospital admission order and randomly divided into observation group (30 cases) and control group (30 cases) according to the random number table method. The control group was treated with conventional treatment, and the observation group with levosimontan on the basis of control group. After a course of treatment, the cardiac function (N terminal-pro brain natriuretic peptide(NT-pro BNP), stroke volume(SV), myocardial activity index (MPI) and blood ejection fraction (LVEF)), clinical efficacy (evaluation of NYHA grading improvement and symptom improvement before and after treatment) and adverse reactions were compared between the two groups. Results The total effective rate in observation group was significantly better than that in control group (P<0.05). After treatment, the levels of NT-pro BNP and MPI in the two groups decreased, while SV and LVEF increased. The difference all had statistical significance (P<0.05). There was no significant difference in potassium, sodium, calcium, chloride, creatinine, urea nitrogen, systolic blood pressure, diastolic blood pressure, heart rate between observation group and control group (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). Conclusion The levosimendan can significantly reduce levels of NT-pro BNP and MPI, increase levels of SV and LVEF in patients with chronic heart failure with dilated cardiomyopathy, and effectively improve heart function. The effect is significant without serious adverse reactions. |
